$2.28
-0.02 (-0.87%)
Open$2.32
Previous Close$2.30
Day High$2.37
Day Low$2.22
52W High$311.36
52W Low—
Volume—
Avg Volume38.5K
Market Cap3.32M
P/E Ratio—
EPS$-91.65
SectorBiotechnology
Analyst Ratings
Strong Buy
6 analysts
Price Target
+1,627.6% upside
Current
$2.28
$2.28
Target
$39.39
$39.39
$26.66
$39.39 avg
$54.88
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.03M | 1.06M | 807.5K |
| Net Income | -278,352 | -347,095 | -248,556 |
| Profit Margin | -27.1% | -32.7% | -30.8% |
| EBITDA | -433,012 | -468,823 | -342,942 |
| Free Cash Flow | -135,403 | -181,532 | -119,491 |
| Rev Growth | +14.1% | -2.0% | +8.2% |
| Debt/Equity | 0.22 | 0.23 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |